Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester, MN, explains her research evaluating the performance of blood-based biomarkers against amyloid-PET in Alzheimer’s disease (AD). In this study, they investigated three Aβ42/Aβ40 assays and two p-tau181 assays in plasma, assessing how they performed against each other in a cohort of individuals without cognitive impairment or with mild cognitive impairment (MCI)/Alzheimer’s disease (AD). Dr Algeciras-Schimnich outlines the ability of each assay to detect abnormal amyloid-PET, finding comparable results for the tau immunoassays, but a stronger performance by the Aβ42/Aβ40 mass spectrometry assay, compared to the immunoassays investigated. Aβ42/40 assays performed better than the p-tau181 assays evaluated, with the combination of both not significantly improving performance versus Aβ42/40 alone. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
